Introduction
Sjogren syndrome is a chronic autoimmune disease in which the immune system targets the body’s moisture-producing glands, especially the salivary glands and lacrimal glands. As a result, the tissues that normally secrete saliva and tears become inflamed and dysfunctional. Although dryness is the best-known feature, Sjogren syndrome is not limited to the eyes and mouth; it is a systemic disorder that can also affect joints, nerves, skin, lungs, kidneys, and other organs. The defining biological processes are immune activation, lymphocytic infiltration of glandular tissue, and gradual disruption of normal secretion.
In healthy people, exocrine glands continuously produce fluid to lubricate surfaces, support digestion, and protect tissues from injury and infection. In Sjogren syndrome, immune-mediated damage interferes with this function. The condition develops through a combination of genetic susceptibility, immune dysregulation, and environmental triggers that lead to chronic inflammation and structural change in affected glands.
The Body Structures or Systems Involved
The main structures involved are the exocrine glands, particularly the lacrimal glands, which produce the watery component of tears, and the salivary glands, which include the parotid, submandibular, sublingual, and smaller minor salivary glands scattered through the mouth and throat. These glands contain secretory epithelial cells organized into acini and ducts. In a healthy state, acinar cells generate fluid and proteins, while ductal cells modify the fluid’s composition and help maintain proper hydration and electrolyte balance.
The eyes depend on the tear film for lubrication, optical clarity, and protection against pathogens and mechanical stress. The tear film is a layered structure containing lipids, aqueous fluid, and mucins, all of which contribute to stability and spread across the ocular surface. The salivary glands serve several functions: they moisten food, begin digestion, buffer acids, protect teeth and mucosal surfaces, and support normal swallowing and speech. When these glands are functioning well, secretion is tightly regulated by autonomic nerves and local signaling molecules.
Sjogren syndrome can also involve other tissues. The immune system may affect joints, producing inflammatory pain and stiffness, and may target the skin, peripheral nerves, lungs, kidneys, and blood vessels. These wider effects reflect the fact that the disease is a systemic immune disorder rather than a problem isolated to glandular tissue.
How the Condition Develops
Sjogren syndrome develops when immune tolerance to certain body tissues breaks down. The exact trigger is not fully known, but the process begins with activation of immune cells against glandular structures, especially the epithelial cells of moisture-producing glands. These cells are not passive targets; in Sjogren syndrome they also act as participants in the inflammatory response by presenting antigens, releasing cytokines, and attracting immune cells.
A central event is infiltration of the glands by lymphocytes, especially T cells and B cells. These immune cells enter the glandular tissue and form organized inflammatory foci around ducts and acini. Instead of remaining confined to the bloodstream or lymphatic system, they accumulate inside the glands and create a persistent inflammatory environment. Cytokines such as interferons, interleukins, and tumor necrosis factor help sustain this response and amplify tissue injury.
As inflammation continues, the glandular epithelium becomes functionally impaired. Secretory cells may lose their ability to respond properly to neural and hormonal signals that normally stimulate fluid production. At the same time, chronic immune attack damages the tissue architecture needed for secretion. The result is not simply less fluid output; the gland becomes less efficient at organizing, concentrating, and releasing secretions in a coordinated way.
B cells are especially important in Sjogren syndrome because they produce autoantibodies and contribute to chronic immune activation. Common autoantibodies include anti-Ro/SSA and anti-La/SSB, which are markers of the autoimmune process and may reflect broader loss of immune tolerance. B-cell activation also promotes hypergammaglobulinemia and can contribute to the formation of immune complexes. Over time, persistent B-cell stimulation increases the risk of lymphoid tissue expansion and, in a small number of cases, lymphoma.
The disease process is therefore both inflammatory and degenerative. Early on, gland function may be reduced because of immune-mediated interference with secretion. Later, repeated inflammation leads to loss of acinar cells, fibrosis, and replacement of glandular tissue with less functional tissue. This shift from reversible dysfunction to structural damage helps explain why Sjogren syndrome can become progressively more persistent over time.
Structural or Functional Changes Caused by the Condition
The most direct functional change in Sjogren syndrome is reduced exocrine secretion. In the eyes, lower tear production destabilizes the tear film, allowing the ocular surface to dry more rapidly between blinks. In the mouth, reduced saliva alters lubrication, buffering capacity, and antimicrobial defense. These changes arise because the glandular cells that normally produce fluid are either inflamed, less responsive to stimulation, or structurally damaged.
At the tissue level, the glands show lymphocytic infiltration, epithelial cell injury, and varying degrees of acinar loss. The acini are the main secretory units, so damage here has a strong effect on overall gland output. Ductal structures may also be altered by inflammation, affecting the movement and composition of glandular fluid. In advanced disease, fibrosis can replace normal glandular tissue, reducing the number of functioning secretory units available.
Immune changes are also characteristic. The condition is associated with activation of autoreactive T and B lymphocytes, increased local production of inflammatory mediators, and the presence of circulating autoantibodies. These immune abnormalities are not simply byproducts of tissue injury; they help sustain the disease by maintaining chronic inflammation and recruiting additional immune cells into the affected glands.
Because the glands become less effective at producing moisture, the body’s surface defenses weaken. Tears normally wash away debris and contain antimicrobial molecules, while saliva contains enzymes and proteins that help control microbial growth. When secretion falls, the mucosal surfaces become more vulnerable to irritation, infection, and mechanical damage. The dysfunction therefore affects both lubrication and protection, altering the normal physiology of the eyes and mouth in parallel.
Factors That Influence the Development of the Condition
Sjogren syndrome appears to arise from an interaction of genetic predisposition, hormonal influences, immune regulation, and environmental exposure. No single cause explains all cases. Instead, the disease develops when a susceptible immune system is pushed toward persistent autoimmune activity against glandular tissues.
Genetic factors contribute to risk by shaping how immune tolerance is established and how immune cells respond to antigen exposure. Variants in genes involved in antigen presentation, interferon signaling, and lymphocyte regulation can make autoimmune activation more likely. Family clustering is not the rule, but inherited immune traits can increase susceptibility.
Hormonal factors are also relevant. Sjogren syndrome occurs much more often in women than in men, suggesting an influence of sex hormones and sex-linked immune regulation. Estrogen and related hormonal pathways may alter B-cell activity, inflammatory signaling, and tissue response to immune injury. This does not mean hormones alone cause the disease, but they may shift the balance toward autoimmunity in predisposed individuals.
Environmental and infectious exposures are thought to influence disease initiation in some cases. Viral infections have been investigated as potential triggers because they can activate innate immune pathways, induce interferon responses, and expose self-antigens during tissue stress. In a genetically susceptible person, such immune activation may help break tolerance and set off a chronic autoimmune cascade. The exact trigger is often not identifiable in an individual patient, but the mechanism is believed to involve immune activation rather than direct gland destruction by an external agent.
Immune system behavior is the most immediate determinant of disease expression. The balance between regulatory and inflammatory immune pathways influences whether gland-targeted autoimmunity remains limited or becomes sustained and systemic. Once lymphocytes are established within the glands, local cytokine networks can perpetuate inflammation even without a continuing external trigger.
Variations or Forms of the Condition
Sjogren syndrome is commonly divided into primary and secondary forms. Primary Sjogren syndrome occurs on its own, without another defined autoimmune disease. Secondary Sjogren syndrome develops alongside another autoimmune disorder, such as rheumatoid arthritis or systemic lupus erythematosus. These forms share core mechanisms, but secondary disease reflects a broader immune background in which multiple tissues may be targeted.
The condition also varies in severity and distribution. In some people, glandular involvement is relatively limited, with inflammation concentrated in salivary and lacrimal glands. In others, the disease is more systemic, with immune activity affecting multiple organs. This variation depends on how broadly the autoimmune response is expressed and which tissues are recruited into the inflammatory process.
Another difference lies between earlier functional disturbance and later structural damage. Some patients have significant gland dysfunction with only modest visible tissue loss, suggesting that immune-mediated signaling defects are affecting secretion before extensive destruction occurs. Others develop progressive fibrosis and acinar loss, which represent a more advanced and less reversible form of the disease. These differences reflect variation in inflammatory intensity, duration, and tissue repair responses.
There are also immunological differences among patients. Some have stronger B-cell activation and higher autoantibody levels, while others show more T-cell-predominant inflammation. These patterns may influence the organs involved and the pace of progression. In this sense, Sjogren syndrome is not a single uniform process but a family of related autoimmune phenotypes centered on exocrine gland dysfunction.
How the Condition Affects the Body Over Time
Over time, continued immune activity can move the disease from functional impairment toward persistent structural change. In the glands, ongoing inflammation reduces the number and efficiency of secretory cells, and repeated injury may be followed by fibrosis. Once glandular tissue is replaced by scar-like tissue, the ability to recover normal secretion declines. This explains why the condition often becomes chronic rather than transient.
The body may partially adapt to reduced secretion, but those adaptations are limited. Mucosal surfaces may become more sensitive to dehydration, friction, and microbial imbalance. The protective functions normally supplied by tears and saliva become less effective. As a result, the local environment of the eyes and mouth changes in ways that can influence tissue integrity, microbial ecology, and surface inflammation.
In systemic disease, chronic immune activation can have broader consequences. Persistent B-cell stimulation may produce abnormal immunoglobulin levels and create a background of ongoing inflammation in the circulation. Some patients develop lung involvement, kidney inflammation, neuropathy, or vasculitis, indicating that the autoimmune process is not confined to exocrine glands. These complications arise because the same immune mechanisms that damage glands can also target other tissues or blood vessels.
There is also a long-term association with lymphoma, especially a type of B-cell lymphoma. This risk reflects chronic B-cell activation and prolonged lymphoid stimulation in affected tissues. The development is uncommon, but it is biologically consistent with a disease characterized by sustained immune stimulation. In that sense, Sjogren syndrome can be viewed not only as a disorder of moisture-secreting glands but also as a chronic immune activation syndrome with potential systemic consequences.
Conclusion
Sjogren syndrome is a chronic autoimmune disease in which the immune system primarily attacks the moisture-producing exocrine glands, especially the salivary and lacrimal glands. Its core biology involves lymphocytic infiltration, inflammatory cytokine signaling, autoantibody production, and progressive disruption of glandular secretion. The condition begins as immune-mediated gland dysfunction and may progress to structural damage, fibrosis, and broader systemic involvement.
Understanding Sjogren syndrome requires seeing both parts of the process: the affected structures and the immune mechanisms that alter them. The disease is defined not just by reduced moisture production, but by the way chronic autoimmunity reshapes glandular tissue and, in some cases, other organs as well. That biological framework explains how the disorder develops and why its effects can extend far beyond the eyes and mouth.